Friday April 23, 2021 0 comments
BOULDER -- Accure Acne, Inc. announced it has launched a private placement offering on the M-Vest platform to raise up to $20 million.
Accure has developed an energy-based device called the "Accure Laser System(R)” that targets sebaceous glands present in skin. Building on the research of R. Rox Anderson, Accure co-founder and chief scientific & medical officer, Accure has developed the Accure Laser System that they believe utilizes a novel, proprietary treatment method that has been demonstrated on human tissue to damage sebaceous glands through selective photothermolysis, while sparing the surrounding epidermis from damage.
In March 2020, Accure's exclusive manufacturing partner for the Accure Laser System, Quanta System S.p.A, received clearance for CE Mark certification. Accure said it believes this is the only 1726nm laser with CE Mark clearance for the treatment of moderate inflammatory acne.
Accure's initial FDA pivotal trial was paused in March 2020 due to the COVID-19 pandemic. In December 2020 Accure received IRB approval to restart their FDA pivotal trial. As a result, the FDA pivotal trial commenced recruiting subjects in December 2020 and resumed treatment in January 2021.
Accure said this investment involves a high degree of risk and should not be made by anyone who cannot afford to lose his or her entire investment. This investment is highly speculative and illiquid and potential investors should read the Accure Acne, Inc. Subscription Agreement & Limited Liability Company Agreement prior to making any investment.
This investment is for accredited investors only. No offer to sell any securities, and no solicitation of an offer to buy any securities, is being made in any jurisdiction in which such offer, sale or solicitation would not be permitted by applicable law, Accure said.